Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
phlebitis/fatiga muscular
L'enllaç es desa al porta-retalls
Pàgina 1 des de 29 resultats
Early detection of sporadic pancreatic cancer: time for change.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Sporadic pancreatic cancer amounts to ∼90% of all pancreatic cancers. It is a gloomy depressive disease and the most recalcitrant malignancy, with a very low 5-year survival (3-6%). At present, diagnostic methods are commonly applied, as used half a century ago, after the appearance of local and
[Chronic venous insufficiency: clinical aspects].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Manifestations of chronic venous insufficiency of the lower limbs are related to congenital or acquired stasis in the deep veins, to post-phlebitis occlusion of the deep veins or to stasis in the superficial veins. Functional impairment may be associated with varicose veins or not. Clinical signs
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
GI147211 is a novel, totally synthetic camptothecin with promising preclinical and early clinical activity. This study was designed to determine the maximum tolerated dose of Gl147211 as a 72-h infusion and to describe its pharmacokinetics and pharmacodynamics on this schedule. In a single-arm,
Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
A Phase Ib trial of bryostatin 1, a macrocyclic lactone and protein kinase C (PKC) activator, was conducted in patients with refractory nonhematological malignancies with the primary goal of determining whether down-regulation of peripheral blood mononuclear cell (PBMNC) PKC activity could be
[A randomized comparative trial of three combined regimens containing cisplatin for treatment of advanced non-small cell lung cancer].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
Vinorelbine (NVB), paclitaxel (TAX), and gemcitabine (GEM) are first-line chemotherapeutic drugs in the treatment for non-small cell lung cancer (NSCLC) currently. There are many domestically retrospective studies to compare efficacies and adverse reactions among these three regimens, all
Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
To determine the toxicities, maximum-tolerated dose (MTD), and pharmacology of etoposide phosphate, a water-soluble etoposide derivative, administered as a 5-minute intravenous infusion on a schedule of days 1, 3, and 5 repeated every 21 days.
METHODS
Thirty-six solid tumor patients with a
[Branch retinal vein occlusion and sarcoidosis in a child: a case report].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
We report a case of branch retinal vein occlusion associated with sarcoidosis in a child. A 13-year-old boy with a history of chronic fatigue was referred for ophthalmologic examination. Fundus examination in the right eye showed periphlebitis of the inferotemporal branch retinal vein, with nerve
[Primary biliary cirrhosis].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Primary biliary cirrhosis is a chronic cholestatic disease which usually affects middle-aged women and is characterized by portal vein inflammation and by segmental and focal necrosis of small intrahepatic bile ducts. The prevalence of the disease is estimated at 8 to 12 cases for 100,000
[Effects of docetaxel and prednisone for hormone-refractory prostate cancer].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
To investigate the role and side effects of docetaxel and prednisone on treating hormone-refractory prostate cancer (HRPC).
METHODS
Docetaxel (75 mg/m(2)) and prednisone (5 mg, bid) were given to 14 patients, whose age range from 51 to 78 years old, of hormone-refractory prostate cancer
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
Gemcitabine and vinorelbine have demonstrated clinical efficacy both as single agents and in combination in patients with metastatic non-small cell lung cancer (NSCLC). This phase II trial evaluated biweekly gemcitabine and vinorelbine in NSCLC patients who have had one prior
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
OBJECTIVE
This study was designed to assess the efficacy of gemcitabine plus vinorelbine using the mouse Lewis lung carcinoma model and to translate this regimen to a phase I clinical study of these two agents in patients with advanced lung cancer.
METHODS
Using the mouse Lewis lung cancer model,
An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
A single-agent dose-escalating phase I and pharmacokinetic study on the naphthalamide agent, LU 79553, was performed to determine its safety profile, maximum tolerated dose (MTD) and recommended dose for phase II studies. LU 79553 was given intravenously (i.v.) every 3 weeks to patients with
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
A dose-escalation, phase I study evaluated the safety, pharmacokinetics, pharmacogenomics, and efficacy of ES-285, a novel agent isolated from a marine mollusc, in adult cancer patients. Patients received a 24-hour i.v. infusion of ES-285 once every 3 weeks until disease progression or unacceptable
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Yondelis (ET-743) is a novel anticancer agent isolated from the marine ascidian Ecteinascidia turbinata. ET-743 possesses potent antitumour activity and a novel mechanism of action at the level of gene transcription. We conducted two sequential phase I dose escalation and pharmacokinetic studies of
[Phase I clinical study on new vinca alkaloid derivative, KW-2307 (vinorelbine). KW-2307 Study Group].
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
Phase I study on a new vinca alkaloid derivative, KW-2307(vinorelbine), was conducted by multiple institutions in 40 patients with a variety of malignant tumors. KW-2307 was given intravenously by single administration or by weekly repeated for 4 weeks (hereinafter as the repeated administration).
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
